Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8438709rdf:typepubmed:Citationlld:pubmed
pubmed-article:8438709lifeskim:mentionsumls-concept:C0018801lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0018787lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0221464lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0019010lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0012963lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0116190lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0205082lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:8438709lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:8438709pubmed:issue3lld:pubmed
pubmed-article:8438709pubmed:dateCreated1993-3-25lld:pubmed
pubmed-article:8438709pubmed:abstractTextThe acute systemic and regional hemodynamic effects of dobutamine (5, 10, and 15 micrograms/kg/min intravenously), of enoximone (1, 1.5, and 2 mg/kg intravenously), and of the dobutamine-enoximone combination were compared in eight patients with severe congestive heart failure. Dobutamine and enoximone similarly and dose-dependently increased cardiac index and decreased systemic vascular resistance, right atrial pressure, and mean capillary wedge pressure. Dobutamine, but not enoximone, increased heart rate after 10 and 15 micrograms/kg/min. The combination of the two drugs caused a greater increase in cardiac index and a greater decrease in total peripheral resistance than did each drug alone. In the forearm vascular bed, brachial blood flow and brachial artery diameter were increased by enoximone significantly and dose-dependently and by dobutamine only at 5 micrograms/kg/min. Finally, the combination of the two drugs increased brachial blood flow but not brachial artery diameter to a larger extent than enoximone alone. Hepatosplanchnic and renal blood flows were not altered by any of the treatments. These results indicate that (1) enoximone exerts a significantly greater muscular vasodilator action than dobutamine; (2) the dobutamine-enoximone combination potentiates the systemic and brachial vasodilator effects of each drug; and (3) high doses of dobutamine (10 and 15 micrograms/kg/min) improve hemodynamics through their positive inotropic and chronotropic effects, whereas at low doses (5 micrograms/kg/min) a peripheral vasodilation also contributes.lld:pubmed
pubmed-article:8438709pubmed:languageenglld:pubmed
pubmed-article:8438709pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8438709pubmed:citationSubsetAIMlld:pubmed
pubmed-article:8438709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8438709pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8438709pubmed:statusMEDLINElld:pubmed
pubmed-article:8438709pubmed:monthMarlld:pubmed
pubmed-article:8438709pubmed:issn0002-8703lld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:GiudicelliJ...lld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:RichardCClld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:ThuillezCClld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:AuzepyPPlld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:AnnaneDDlld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:BellissantEElld:pubmed
pubmed-article:8438709pubmed:authorpubmed-author:TeboulJ LJLlld:pubmed
pubmed-article:8438709pubmed:issnTypePrintlld:pubmed
pubmed-article:8438709pubmed:volume125lld:pubmed
pubmed-article:8438709pubmed:ownerNLMlld:pubmed
pubmed-article:8438709pubmed:authorsCompleteYlld:pubmed
pubmed-article:8438709pubmed:pagination799-808lld:pubmed
pubmed-article:8438709pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:meshHeadingpubmed-meshheading:8438709-...lld:pubmed
pubmed-article:8438709pubmed:year1993lld:pubmed
pubmed-article:8438709pubmed:articleTitleArterial hemodynamics and cardiac effects of enoximone, dobutamine, and their combination in severe heart failure.lld:pubmed
pubmed-article:8438709pubmed:affiliationDepartment of Clinical Pharmacology, Hôpital de Bicêtre, France.lld:pubmed
pubmed-article:8438709pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8438709pubmed:publicationTypeComparative Studylld:pubmed